Navigation Links
H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide
Date:5/1/2009

Replikins, Ltd. has announced that it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, which is ready for testing worldwide. The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way.

London, UK (PRWEB) May 1, 2009 -- Replikins, Ltd. has announced that it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, which is ready for testing worldwide.

The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way.

In April 2008, Replikins, Ltd announced the likelihood of H1N1 outbreaks based on the company's patented Replikin Count™ genomics technology, which examines specific regions in virus genes that have been linked with past epidemics. The company's chairman, Dr. Samuel Bogoch, found that the regions have been conserved for decades. In H1N1 last year the company detected the highest concentrations of these specific regions ever seen, except for those from the 1918 flu pandemic which killed tens of millions of people. To date, no other method has been able to predict whether and what strain of a given organism will threaten a human or animal population.

The company is producing the new product after achieving test results against two previous viral outbreaks: the lethal Taura virus with shrimp populations and the avian flu (H5N1) with chicken populations. The company's closely related Replikins vaccine against avian flu, produced in a 7 day period, was recently tested at the University of Georgia and shown to block H5N1 virus entry, replication, and excretion in chickens (paper submitted for publication).

Institutions requesting Replikins' H1N1 vaccine for testing should contact: jmckenney @ replikins.com

http://www.replikins.com

# # #

Read the full story at http://www.prweb.com/releases/2009/05/prweb2384744.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
2. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
3. Hoviones TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
4. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
5. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
6. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
10. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
11. DaVita Launches Flu Fighter Program in Support of National Influenza Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... , June 23, 2016 ... Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... , the peer-reviewed journal from touchONCOLOGY, Andrew ... escalating cost of cancer care is placing an ... result of expensive biologic therapies. With the patents ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
Breaking Biology News(10 mins):